Hospitalization for chronic obstructive pulmonary disease and pneumonia: association with the dose of inhaled corticosteroids. A nation-wide cohort study of 52 100 outpatients.

[1]  J. Vestbo,et al.  Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD , 2022, European Respiratory Journal.

[2]  R. Dessau,et al.  Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease , 2020, Thorax.

[3]  P. Dorinsky,et al.  Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. , 2020, The New England journal of medicine.

[4]  S. Suissa,et al.  Comparative effects of LAMA-LABA-ICS versus LAMA-LABA for COPD: Cohort study in real world clinical practice: LAMA-LABA-ICS versus LAMA-LABA in COPD. , 2019, Chest.

[5]  D. Price,et al.  Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study , 2019, npj Primary Care Respiratory Medicine.

[6]  Meilan K. Han,et al.  Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. , 2019, The Lancet. Respiratory medicine.

[7]  N. Seersholm,et al.  COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months , 2019, BMJ Open Respiratory Research.

[8]  K. Rabe,et al.  Inhaled corticosteroids in COPD: friend or foe? , 2018, European Respiratory Journal.

[9]  Meilan K. Han,et al.  Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD , 2018, The New England journal of medicine.

[10]  D. Musher,et al.  Mortality in Patients Admitted for Concurrent COPD Exacerbation and Pneumonia , 2017, COPD.

[11]  P. Lange,et al.  Danish Register of chronic obstructive pulmonary disease , 2016, Clinical epidemiology.

[12]  H. Magnussen,et al.  Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. , 2016, The Lancet. Respiratory medicine.

[13]  Aziz Sheikh,et al.  Global and regional estimates of COPD prevalence: Systematic review and meta–analysis , 2015, Journal of global health.

[14]  F. Martinez,et al.  Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. , 2015, Annals of the American Thoracic Society.

[15]  James R Carpenter,et al.  Multiple imputation of covariates by fully conditional specification: Accommodating the substantive model , 2012, Statistical methods in medical research.

[16]  S. Suissa,et al.  Inhaled corticosteroids in COPD and the risk of serious pneumonia , 2013, Thorax.

[17]  Henrik Toft Sørensen,et al.  Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions , 2012, Clinical epidemiology.

[18]  Elsebeth Lynge,et al.  The Danish National Patient Register , 2011, Scandinavian journal of public health.

[19]  S. Suissa,et al.  Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. , 2011, American journal of respiratory and critical care medicine.

[20]  T. Welte,et al.  Clinical and economic burden of community-acquired pneumonia among adults in Europe , 2010, Thorax.

[21]  P. Jones,et al.  Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results , 2009, European Respiratory Journal.

[22]  A. Anzueto,et al.  Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. , 2008, Respiratory medicine.

[23]  Z. Mosenifar,et al.  Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease. , 2008, Proceedings of the American Thoracic Society.

[24]  C. McDonald,et al.  Rising incidence and persistently high mortality of hospitalized pneumonia: a 10‐year population‐based study in Denmark , 2006, Journal of internal medicine.

[25]  D G Altman,et al.  Calculating the number needed to treat for trials where the outcome is time to an event , 1999, BMJ.

[26]  L. Fabbri,et al.  Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. , 1996, Thorax.